Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 CAD | -.--% |
|
-.--% | -60.00% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 2.668 | 3.113 | 34.74 | 10.27 | 2.74 | 3.424 |
Enterprise Value (EV) 1 | 1.964 | 3.148 | 33.24 | 8.032 | 1.23 | 2.486 |
P/E ratio | -2.44 x | -2.7 x | -22.5 x | -10.4 x | -4.69 x | -13.5 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -1.99 x | -2.85 x | -24.8 x | -8.31 x | -2.11 x | -9.87 x |
EV / FCF | -2.26 x | -18.8 x | -55 x | -11.4 x | -2.39 x | -5.34 x |
FCF Yield | -44.2% | -5.31% | -1.82% | -8.74% | -41.9% | -18.7% |
Price to Book | 6.13 x | -5.34 x | 44.3 x | 6.04 x | 2.41 x | 3.84 x |
Nbr of stocks (in thousands) | 88,929 | 88,929 | 115,809 | 136,979 | 136,979 | 136,979 |
Reference price 2 | 0.0300 | 0.0350 | 0.3000 | 0.0750 | 0.0200 | 0.0250 |
Announcement Date | 23/04/19 | 27/04/20 | 29/04/21 | 29/04/22 | 27/04/23 | 29/04/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -0.985 | -1.106 | -1.343 | -0.967 | -0.582 | -0.252 |
EBIT 1 | -1.041 | -1.143 | -1.347 | -0.986 | -0.584 | -0.254 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -1.047 | -1.154 | -1.358 | -0.986 | -0.584 | -0.254 |
Net income 1 | -1.047 | -1.154 | -1.358 | -0.986 | -0.584 | -0.254 |
Net margin | - | - | - | - | - | - |
EPS 2 | -0.0123 | -0.0130 | -0.0133 | -0.007244 | -0.004263 | -0.001854 |
Free Cash Flow 1 | -0.8684 | -0.1672 | -0.6048 | -0.7022 | -0.515 | -0.4658 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 23/04/19 | 27/04/20 | 29/04/21 | 29/04/22 | 27/04/23 | 29/04/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | 0.04 | - | - | - | - |
Net Cash position 1 | 0.7 | - | 1.5 | 2.24 | 1.51 | 0.94 |
Leverage (Debt/EBITDA) | - | -0.0316 x | - | - | - | - |
Free Cash Flow 1 | -0.87 | -0.17 | -0.6 | -0.7 | -0.52 | -0.47 |
ROE (net income / shareholders' equity) | 4,027% | 1,559% | -1,229% | -78.8% | -41.2% | -25.1% |
ROA (Net income/ Total Assets) | -108% | -130% | -90.2% | -31.2% | -19.1% | -12.6% |
Assets 1 | 0.9655 | 0.8844 | 1.505 | 3.157 | 3.061 | 2.014 |
Book Value Per Share 2 | 0 | -0.0100 | 0.0100 | 0.0100 | 0.0100 | 0.0100 |
Cash Flow per Share 2 | 0.0100 | 0 | 0.0100 | 0.0200 | 0.0100 | 0.0100 |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 23/04/19 | 27/04/20 | 29/04/21 | 29/04/22 | 27/04/23 | 29/04/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-60.00% | 1M | |
+20.63% | 127B | |
+25.07% | 27.67B | |
-20.17% | 20.33B | |
-17.31% | 16.79B | |
-18.07% | 15.63B | |
-47.70% | 14.65B | |
+11.92% | 14.84B | |
+58.32% | 14.43B | |
+149.98% | 12.49B |
- Stock Market
- Equities
- VXL Stock
- Financials Vaxil Bio Ltd.